March 16, 2021 06:52
value
British pharmaceuticals AstraZeneca announced this march 16 march of 2021 an agreement with the united states for the year of 500 000 dosage additional of a possible treatment against the covid with anticuerpos, who, if authorized, could protect it virus to the people who can not be vacancy.
In a communicated, the company explained that the pact with the Department of Health and Human Services (HHS, in English) y el Department of Defense ampli otro agreement of October 2020 by the EE.UU. received 100,000 initial doses of pharmacy AZD7442, with the option to purchase more in 2021, and compromise to meet the ultimate phase of the clinical studies.
With the 500,000 extra doses announced this March 16th and another 100,000 more agreed in parallel with Defense, AstraZeneca could sum up to Washington of 2021 hasta 700 000 dosage del medicamento, señala en la nota.
“The combination of anticuerpos with effect a large place has the potential to offer protection cases where those who are not able to vacate, in order to prevent it contagio how to treat it enfermedad in patients and contagious “, affirmed the pharmaceutical delegate, Pascal Soirot.
“El apoyo del Government of the United States is critical to accelerate the development of AZD7442, which we believe will be a herramienta important in the case of the covid-19 “, added.
The pharmacy designed to reduce the resistance The most potent variants of the virus are currently being evaluated in clinical trials teen 9 000 volunteers in various parts of the world, indicates the communiqué.
AstraZeneca signals that the total value of the akuerdos con el Gobierno estadounidense para el desarrollo y el suministro of AZD7442 during 2021 ascending to 726 million dollars.